pyrazines has been researched along with withanolides in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Casadonte, F; FocĂ , D; Macrina, L; Malara, N; Santoro, L; Savino, R; Scaramuzzino, M; Sesto, MF; Terracciano, R | 1 |
Aqil, F; Bansal, SS; Gupta, RC; Jeyabalan, J; Kausar, H; Sharma, RJ; Singh, IP; Vadhanam, MV | 1 |
2 other study(ies) available for pyrazines and withanolides
Article | Year |
---|---|
Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells.
Topics: Adenoviridae; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Coumarins; Ergosterol; Genetic Vectors; Humans; Interleukin-6; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; S Phase; Signal Transduction; STAT3 Transcription Factor; Withanolides | 2008 |
Multi-layer polymeric implants for sustained release of chemopreventives.
Topics: Animals; Anticarcinogenic Agents; Biological Availability; Coated Materials, Biocompatible; Curcumin; DNA Adducts; Female; Humans; Infusion Pumps, Implantable; Mice; Mice, Nude; Polyesters; Polymers; Pyrazines; Thiones; Thiophenes; Tissue Distribution; Withanolides; Xenograft Model Antitumor Assays | 2012 |